Imugene embarks on $95 million capital raise to fund clinical pipeline into 2025
The biotech’s multi-million-dollar capital raise will support development opportunities across its clinical portfolio over the next four years. Imugene has set out to raise $95 million to support its clinical pipeline.
Imugene Limited (ASX:IMU, OTC:IUGNF) has embarked on a A$95 million capital raise, establishing a funding runway that will financially support its clinical trial pipeline through 2025.
The Australia-headquartered biotech has already received firm commitments to raise A$90 million through a placement executed at 30 cents per share and now hopes to secure a further A$5 million via a share purchase plan (SPP) at the same price.
BARD1 Life Sciences raises $15 million to accelerate cancer diagnostic test development
Chairman Dr Geoff Cumming said: “The capital raising was strongly supported by new and existing institutional and sophisticated investors with a deep understanding of the biotechnology sector and importance of early cancer detection on patient outcomes.” Shareholders will be offered the opportunity to participate in a Share Purchase Plan to raise up to a further $2 million.
BARD1 Life Sciences Ltd has raised $15 million in a placement to sophisticated, institutional and professional investors to accelerate the development and commercialisation of its cancer diagnostic test development program.
The company has completed the placement with strong demand from new and existing, institutional and sophisticated investors in Australia and Hong Kong.
Unremarkable day on Asian stock markets, dollar too ends mixed
21 May 2021, 17:30 GMT+10
SYDNEY, NSW, Australia - Shares in Australia and Hong Kong were basically flat on Friday, while in Japan stocks rose. On the Chinese mainland, sharemarkets closed lower.
The Australian All Ordinaries ended with a 12.70 points or 0.18 percent gain to 7,265.30. After a near 2% fall Wednesday yesterday our market rose 1.3% and is currently flat today. The bounce-back was driven by the previously unloved tech sector (especially the PNPL subsector) and the big banks whilst mining stocks underperformed which was surprising as Citi put through upgrades to their Copper and Aluminium forecasts which saw eps upgrades for 21/22 of between 5 9% for BHP and RIO and which saw dividends lifted to 9.3 11.4% ff to BHP and 17.4 14% ff for RIO way above the banks, Gordon Orr of Bell Potter Securities in Mackay, Queensland, Australia, said in a note to clients late Friday.
Nikkei 225 in Tokyo jumps 220 points, broader market mixed
Lola Evans
21 May 2021, 17:30 GMT+10
Shares in Australia and Hong Kong were basically flat on Friday, while in Japan stocks rose.
The Australian All Ordinaries ended with a 12.70 points or 0.18 percent gain to 7,265.30. After a near 2% fall Wednesday yesterday our market rose 1.3% and is currently flat today.
SYDNEY, NSW, Australia - Shares in Australia and Hong Kong were basically flat on Friday, while in Japan stocks rose. On the Chinese mainland, sharemarkets closed lower.
The Australian All Ordinaries ended with a 12.70 points or 0.18 percent gain to 7,265.30. After a near 2% fall Wednesday yesterday our market rose 1.3% and is currently flat today. The bounce-back was driven by the previously unloved tech sector (especially the PNPL subsector) and the big banks whilst mining stocks underperformed which was surprising as Citi put through upgrades to their Copper and Aluminium forecasts which saw eps upgrades fo